<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03341156</url>
  </required_header>
  <id_info>
    <org_study_id>PRO17080509</org_study_id>
    <nct_id>NCT03341156</nct_id>
  </id_info>
  <brief_title>Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart Transplantation</brief_title>
  <acronym>OPSTAHT</acronym>
  <official_title>Optimized Administration of Prothrombin Complex Concentrate (PCC) vs. Standard Transfusion During/After Heart Transplantation - OPSTAHT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kathirvel Subramaniam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Maryland, College Park</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is comparing the use of Kcentra vs. standard transfusion in patients undergoing
      heart transplantation surgery. Half of the patients will receive Kcentra, while the other
      half will receive fresh frozen plasma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a randomized (1:1; PCC vs. plasma), open-label trial of hemostatic
      therapies during heart transplantation. The goal is to enroll 60 patients. Informed consent
      will be obtained from patients meeting the inclusion and exclusion criteria before the
      initiation of any study specific procedures. Eligible patients will be randomized to receive
      either PCC or plasma transfusion. The efficacy of interventions will be evaluated after 30
      minutes of protamine administration. After the heart transplantation, thrombocytopenia and/or
      hypofibrinogenemia may worsen bleeding associated with vitamin K dependent factor
      deficiencies. Transfusion of platelets and/or cryoprecipitate is permitted if abnormal
      laboratory values are observed during the rewarming phase of CPB; platelet count &lt;100 x
      103/µl, and fibrinogen &lt;200 mg/dl, respectively. Laboratory tests (hematocrit, platelet
      count, PT, PTT, POC-PT, coagulation factor and inhibitor levels (e.g., factor II,
      antithrombin), thromboelastometry or thromboelastography, endogenous thrombin generation)
      will also be obtained at baseline, twice during surgery and at 12-24 hours after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of Chest Tube Drainage</measure>
    <time_frame>From patient out of room time until 24 hours after</time_frame>
    <description>Primary outcome: Amount of chest tube output in the first 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative INR</measure>
    <time_frame>30 Minutes post-treatment (after the last dose is completed)</time_frame>
    <description>INR value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Product Use</measure>
    <time_frame>In OR (from OR entry to OR out of room time); postoperatively (patient out of room time) to 24 hours after; from 24 hours after until 30 days post surgery or until discharge (whichever comes first)</time_frame>
    <description>Total hemostatic blood product use including plasma, platelets, cryoprecipitate, and recombinant activated factor VII.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cell Use</measure>
    <time_frame>Intraoperatively(from start of first intervention until start of second intervention;after 2nd intervention(post-bypass)until patient out of room time) &amp; Postoperatively(from patient out of room time until 24 hours after;24 hours after until 30 days)</time_frame>
    <description>Red Blood Cell Use Intraoperatively and Postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for circulatory support</measure>
    <time_frame>30 days post-operative or until discharge (whichever comes first)</time_frame>
    <description>Percentage of patients who needed circulatory support (ECMO or VAD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical Ventilation</measure>
    <time_frame>30 days post-operative or until discharge (whichever comes first)</time_frame>
    <description>Percentage of patients who needed mechanical ventilation for more than 72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tracheostomy</measure>
    <time_frame>30 days post-operative or until discharge (whichever comes first)</time_frame>
    <description>Percentage of patients who needed a tracheostomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Failure</measure>
    <time_frame>30 days post-operative or until discharge (whichever comes first)</time_frame>
    <description>Percentage of patients who experience renal failure requiring dialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sepsis</measure>
    <time_frame>30 days post-operative or until discharge (whichever comes first)</time_frame>
    <description>Percentage of patients who experienced sepsis infection morbidity consisted of sepsis syndrome, septic shock, or mediastinitis. In addition, the diagnosis of sepsis included organisms isolated from the cultures along with elevated temperature and white blood cell counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>30 days post-operative or until discharge (whichever comes first)</time_frame>
    <description>Percentage of patients who died</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke or postoperative neurological dysfunction</measure>
    <time_frame>30 days post-operative or until discharge (whichever comes first)</time_frame>
    <description>Percentage of patients who experienced a stroke or postoperative neurological dysfunction (seizures, delirium, unconsciousness, encephalopathy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal complication requiring bowel resection</measure>
    <time_frame>30 days post-operative or until discharge (whichever comes first)</time_frame>
    <description>Percentage of patients who experienced gastrointestinal complications requiring bowel resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral vascular complication</measure>
    <time_frame>30 days post-operative or until discharge (whichever comes first)</time_frame>
    <description>Percentage of patients who experience peripheral vascular complications requiring surgery (thrombectomy, bypass, and amputations)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deep Vein Thrombosis and Pulmonary Thromboembolism</measure>
    <time_frame>30 days post-operative or until discharge (whichever comes first)</time_frame>
    <description>Percentage of patients who develop a deep vein thrombosis and/ or pulmonary thromboembolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Coagulation Factor levels</measure>
    <time_frame>At baseline, post-bypass/pre-protamine, 30 minutes post-protamine, 12-24 hours post treatment</time_frame>
    <description>Plasma coagulator factor levels will be analyzed via blood laboratory tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin Generation Assay</measure>
    <time_frame>At baseline, post-bypass/pre-protamine, 30 minutes post-protamine, 12-24 hours post treatment</time_frame>
    <description>Thrombin Generation assay will be analyzed via blood laboratory tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Re-exploration</measure>
    <time_frame>30 days post-operative or until discharge (whichever comes first)</time_frame>
    <description>Surgical Re-Exploration that is related to heart transplant surgery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Direct Cost Benefit</measure>
    <time_frame>From infusion until 30 days post heart transplant</time_frame>
    <description>Acquisition costs for test agents and blood bank related charges (thawing, etc.)</description>
  </other_outcome>
  <other_outcome>
    <measure>Total surgical time</measure>
    <time_frame>From anesthesia start time until anesthesia stop time</time_frame>
    <description>Total time of surgical duration will be measured in the corresponding time frame</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to hospital discharge</measure>
    <time_frame>From patient out of room time to hospital discharge (or 30 days post heart transplant, whichever comes first)</time_frame>
    <description>Time until discharge from the hospital post study intervention will be measured</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to Intensive Care Unit (ICU) discharge</measure>
    <time_frame>From patient out of room time to ICU discharge (or 30 days post heart transplant, whichever comes first)</time_frame>
    <description>Time until discharge from the ICU post study intervention will be measured</description>
  </other_outcome>
  <other_outcome>
    <measure>Indirect Cost Benefits</measure>
    <time_frame>From last intervention/infusion until 30 days post heart transplant or until discharge</time_frame>
    <description>Extra costs related to study drug (PCC and plasma) related complications (volume overload, thrombotic complications)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Disease End Stage</condition>
  <condition>Heart Failure，Congestive</condition>
  <arm_group>
    <arm_group_label>Kcentra (PCC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Half of subjects enrolled will be randomized to the Kcentra (PCC) group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Frozen Plasma Product, Human</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half of subjects enrolled will be randomized to the standard transfusion group and receive fresh frozen plasma intra-operatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kcentra</intervention_name>
    <description>Kcentra will be administered in 2 divided doses; Pre-bypass (5-10 units/kg based on body weight and preoperative INR and post-protamine based of the pre-bypass dose and the preoperative INR; daily maximum dose not to exceed 5000 IU (50 IU/kg)</description>
    <arm_group_label>Kcentra (PCC)</arm_group_label>
    <other_name>prothrombin complex concentrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Frozen Plasma Product, Human</intervention_name>
    <description>If the patient is randomized to receive standard transfusion they will receive 2 U of fresh frozen plasma intravenously before cardiopulmonary bypass and then up to 4-8 U of plasma added to the cardiopulmonary bypass reservoir during rewarming.</description>
    <arm_group_label>Frozen Plasma Product, Human</arm_group_label>
    <other_name>Fresh Frozen Plasma</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be willing and able to provide written informed consent.

          -  Be at least 18 years of age.

          -  Patients with or without ventricular assist device (VAD) undergoing heart
             transplantation

          -  Patients who have been on warfarin for at least 72 hours before cardiopulmonary bypass
             procedures for heart transplantation.

          -  International normalization ration (INR) greater than or equal to 1.5

          -  Body temperature greater than 35.0 degrees Celsius.

          -  Blood pH greater than 7.2

          -  Hemoglobin greater than 7.0 mg/dL.

        Exclusion Criteria:

          -  Treatment with clopidogrel, prasugrel, or ticagrelor within 5 days prior to study
             surgery.

          -  Known or suspected thrombophilia such as factor V Leiden, hereditary antithrombin III
             deficiency, heparin-induced thrombocytopenia, disseminated intravascular coagulation.

          -  Ischemic or thromboembolic events within 6 weeks of study surgery.

          -  Known allergy/anaphylaxis to prothrombin complex concentrate or albumin.

          -  Any indication that a potential subject did not comprehend the study restrictions,
             procedures. or consequences therein an informed consent cannot be convincingly given.

          -  Patients on respiratory support including extracorporeal membrane oxygenation (ECMO) .

          -  Life expectancy less than 48 hours.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenichi Tanaka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathirvel Surbramaniam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Monroe</last_name>
    <phone>412-623-6382</phone>
    <email>Monroeal@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline E. Kostishack</last_name>
    <phone>412-623-1586</phone>
    <email>caroline.kostishack@chp.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenichi Tanaka, M.D.</last_name>
      <phone>410-328-9813</phone>
    </contact>
    <contact_backup>
      <last_name>LaToya Stubbs</last_name>
      <email>lstubbs@som.umaryland.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Upmc Presbyterian Montefiore Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>KATHIRVEL SUBRAMANIAM, MD</last_name>
      <phone>412-647-5635</phone>
      <email>subramaniamk@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>AMY MONROE, MPH</last_name>
      <phone>4126096161</phone>
      <email>monroeal@upmc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian Shadyside</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathirvel Subramaniam, M.D.</last_name>
      <phone>412-647-5635</phone>
      <email>subramaniamk@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amy Monroe</last_name>
      <phone>4126236382</phone>
      <email>Monroeal@upmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bolliger D, Görlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology. 2010 Nov;113(5):1205-19. doi: 10.1097/ALN.0b013e3181f22b5a. Review.</citation>
    <PMID>20881594</PMID>
  </reference>
  <reference>
    <citation>Mathias T, Puca KE, Downey F, Boyle AJ: Use of Vitamin K and Prothrombin Complex Concentrate as Warfarin Reversal Prior to Heart Transplant. Journal of Heart and Lung Transplantation 2012; 31: S154</citation>
  </reference>
  <reference>
    <citation>Kantorovich A, Fink JM, Militello MA, Wanek MR, Smedira NG, Soltesz EG, Moazami N. Low-dose 3-factor prothrombin complex concentrate for warfarin reversal prior to heart transplant. Ann Pharmacother. 2015 Aug;49(8):876-82. doi: 10.1177/1060028015585344. Epub 2015 May 18.</citation>
    <PMID>25986007</PMID>
  </reference>
  <reference>
    <citation>Marshall AL, Levine M, Howell ML, Chang Y, Riklin E, Parry BA, Callahan RT, Okechukwu I, Ayres AM, Nahed BV, Goldstein JN. Dose-associated pulmonary complication rates after fresh frozen plasma administration for warfarin reversal. J Thromb Haemost. 2016 Feb;14(2):324-30. doi: 10.1111/jth.13212. Epub 2016 Feb 2.</citation>
    <PMID>26644327</PMID>
  </reference>
  <reference>
    <citation>Demeyere R, Gillardin S, Arnout J, Strengers PF. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang. 2010 Oct;99(3):251-60. doi: 10.1111/j.1423-0410.2010.01339.x.</citation>
    <PMID>20840339</PMID>
  </reference>
  <reference>
    <citation>Tanaka KA, Mazzeffi MA, Grube M, Ogawa S, Chen EP. Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion. 2013 Apr;53(4):920-1. doi: 10.1111/trf.12110.</citation>
    <PMID>23565996</PMID>
  </reference>
  <reference>
    <citation>Song HK, Tibayan FA, Kahl EA, Sera VA, Slater MS, Deloughery TG, Scanlan MM. Safety and efficacy of prothrombin complex concentrates for the treatment of coagulopathy after cardiac surgery. J Thorac Cardiovasc Surg. 2014 Mar;147(3):1036-40. doi: 10.1016/j.jtcvs.2013.11.020. Epub 2013 Dec 22.</citation>
    <PMID>24365268</PMID>
  </reference>
  <reference>
    <citation>Rao VK, Lobato RL, Bartlett B, Klanjac M, Mora-Mangano CT, Soran PD, Oakes DA, Hill CC, van der Starre PJ. Factor VIII inhibitor bypass activity and recombinant activated factor VII in cardiac surgery. J Cardiothorac Vasc Anesth. 2014 Oct;28(5):1221-6. doi: 10.1053/j.jvca.2014.04.015.</citation>
    <PMID>25281040</PMID>
  </reference>
  <reference>
    <citation>Balsam LB, Timek TA, Pelletier MP. Factor eight inhibitor bypassing activity (FEIBA) for refractory bleeding in cardiac surgery: review of clinical outcomes. J Card Surg. 2008 Nov-Dec;23(6):614-21. doi: 10.1111/j.1540-8191.2008.00686.x. Epub 2008 Sep 10.</citation>
    <PMID>18793226</PMID>
  </reference>
  <reference>
    <citation>Ortmann E, Besser MW, Sharples LD, Gerrard C, Berman M, Jenkins DP, Klein AA. An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. Anesth Analg. 2015 Jul;121(1):26-33. doi: 10.1213/ANE.0000000000000689.</citation>
    <PMID>25822921</PMID>
  </reference>
  <reference>
    <citation>Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015 May 23;385(9982):2077-87. doi: 10.1016/S0140-6736(14)61685-8. Epub 2015 Feb 27.</citation>
    <PMID>25728933</PMID>
  </reference>
  <reference>
    <citation>Tanaka KA, Mazzeffi MA, Strauss ER, Szlam F, Guzzetta NA. Computational simulation and comparison of prothrombin complex concentrate dosing schemes for warfarin reversal in cardiac surgery. J Anesth. 2016 Jun;30(3):369-76. doi: 10.1007/s00540-015-2128-3. Epub 2016 Jan 9.</citation>
    <PMID>26749482</PMID>
  </reference>
  <reference>
    <citation>Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, Goldstein JN. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013 Sep 10;128(11):1234-43. doi: 10.1161/CIRCULATIONAHA.113.002283. Epub 2013 Aug 9.</citation>
    <PMID>23935011</PMID>
  </reference>
  <reference>
    <citation>CSLBehring: Prescribing informaiton for Kcentra (Prothrombin complex concentrate, human). Kankakee, IL, CSL Behring 2014, pp September 15. Subramaniam K. Early graft failure after heart transplantation: prevention and treatment. Int Anesthesiol Clin. 2012 Summer;50(3):202-27.</citation>
  </reference>
  <reference>
    <citation>Tholpady A, Monson J, Radovancevic R, Klein K, Bracey A. Analysis of prolonged storage on coagulation Factor (F)V, FVII, and FVIII in thawed plasma: is it time to extend the expiration date beyond 5 days? Transfusion. 2013 Mar;53(3):645-50. doi: 10.1111/j.1537-2995.2012.03786.x. Epub 2012 Jul 15.</citation>
    <PMID>22803679</PMID>
  </reference>
  <reference>
    <citation>Scott E, Puca K, Heraly J, Gottschall J, Friedman K. Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6°C storage. Transfusion. 2009 Aug;49(8):1584-91. doi: 10.1111/j.1537-2995.2009.02198.x.</citation>
    <PMID>19413730</PMID>
  </reference>
  <reference>
    <citation>Karkouti K, McCluskey SA, Syed S, Pazaratz C, Poonawala H, Crowther MA. The influence of perioperative coagulation status on postoperative blood loss in complex cardiac surgery: a prospective observational study. Anesth Analg. 2010 Jun 1;110(6):1533-40. doi: 10.1213/ANE.0b013e3181db7991. Epub 2010 Apr 30.</citation>
    <PMID>20435945</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 28, 2017</study_first_submitted>
  <study_first_submitted_qc>November 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>October 23, 2019</last_update_submitted>
  <last_update_submitted_qc>October 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Kathirvel Subramaniam</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Heart transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

